Pasar al contenido principal

RELEVANCIA FISIOLOGICA Y TERAPEUTICA DE LAS QUINASAS Y FOSFATASAS MITOTICAS

SAF2015-69920-R

•
Nombre agencia financiadora Ministerio de Economía y Competitividad
Acrónimo agencia financiadora MINECO
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2015
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Unidad de gestión Dirección General de Investigación Científica y Técnica
Centro beneficiario FUNDACION SECTOR PUBLICO ESTATAL CENTRO NACIONAL INVESTIGACIONES ONCOLOGICAS CARLOS III
Identificador persistente http://dx.doi.org/10.13039/501100003329

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Biochemical analyses reveal amino acid residues critical for cell cycle-dependent phosphorylation of human Cdc14A phosphatase by cyclin-dependent kinase 1

  • Ovejero, Sara
  • Ayala, Patricia
  • Malumbres, Marcos
  • Pimentel-Muiños, Felipe X.
  • Bueno, Avelino
  • Sacristán, María P.
Cdc14 enzymes compose a family of highly conserved phosphatases that are present in a wide range of organisms, including yeast and humans, and that preferentially reverse the phosphorylation of Cyclin-Dependent Kinase (Cdk) substrates. The budding yeast Cdc14 orthologue has essential functions in the control of late mitosis and cytokinesis. In mammals, however, the two Cdc14 homologues, Cdc14A and Cdc14B, do not play a prominent role in controlling late mitotic events, suggesting that some Cdc14 functions are not conserved across species. Moreover, in yeast, Cdc14 is regulated by changes in its subcellular location and by phosphorylation events. In contrast, little is known about the regulation of human Cdc14 phosphatases. Here, we have studied how the human Cdc14A orthologue is regulated during the cell cycle. We found that Cdc14A is phosphorylated on Ser411, Ser453 and Ser549 by Cdk1 early in mitosis and becomes dephosphorylated during late mitotic stages. Interestingly, in vivo and in vitro experiments revealed that, unlike in yeast, Cdk1-mediated phosphorylation of human Cdc14A did not control its catalytic activity but likely modulated its interaction with other proteins in early mitosis. These findings point to differences in Cdk1-mediated mechanisms of regulation between human and yeast Cdc14 orthologues., This work was funded by grants from the Spanish Ministry of Economy, Industry and Competitiveness (MINECO; BFU2015-69709-P and SAF2015-69920-R). S.O. was supported by a FPU fellowship from the Spanish Ministry of Education and P.A. was supported by a JAE-Predoctoral fellowship from the Spanish National research Council (CSIC).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Thrombocytopenia-associated mutations in Ser/Thr kinase MASTL deregulate actin cytoskeletal dynamics in platelets

  • Hurtado, Begoña
  • Trakala, Marianna
  • Ximénez-Embún, Pilar
  • El Bakkali, Aicha
  • Partida, David
  • Sanz-Castillo, Belén
  • Álvarez-Fernández, Mónica
  • Maroto, María
  • Sánchez-Martínez, Ruth
  • Martínez, Lola
  • Redondo-Muñoz, Javier
  • García de Frutos, Pablo
  • Malumbres, Marcos
MASTL, a Ser/Thr kinase that inhibits PP2A-B55 complexes during mitosis, is mutated in autosomal dominant thrombocytopenia. However, the connections between the cell-cycle machinery and this human disease remain unexplored. We report here that, whereas Mastl ablation in megakaryocytes prevented proper maturation of these cells, mice carrying the thrombocytopenia-associated mutation developed thrombocytopenia as a consequence of aberrant activation and survival of platelets. Activation of mutant platelets was characterized by hyperstabilized pseudopods mimicking the effect of PP2A inhibition and actin polymerization defects. These aberrations were accompanied by abnormal hyperphosphorylation of multiple components of the actin cytoskeleton and were rescued both in vitro and in vivo by inhibiting upstream kinases such as PKA, PKC, or AMPK. These data reveal an unexpected role of Mastl in actin cytoskeletal dynamics in postmitotic cells and suggest that the thrombocytopenia-associated mutation in MASTL is a pathogenic dominant mutation that mimics decreased PP2A activity resulting in altered phosphorylation of cytoskeletal regulatory pathways., BH and RSM were supported by the Juan de la Cierva Programme of the Spanish Ministry of Economy and Competitiveness (MINECO). MT was supported by the Foundation La Caixa. AEB was supported by the Programa de Empleo Juvenil, Comunidad de Madrid. MAF received a young investigator grant from MINECO (SAF2014-60442-JIN, cofinanced by FEDER funds). PGDF was supported by the Fundació la Marató de TV3 (projects 080121 and 20153031). JM was supported by the Ramon y Cajal Programme (MINECO; RYC-2012-10651). The laboratory of MM is supported by grants from MINECO (SAF2015-69920-R); the Programa iLUNG from the Comunidad de Madrid (B2017/BMD-3884); and Worldwide Cancer Research (15-0278). CNIO is a Severo Ochoa Center of Excellence (MINECO award SEV-2015-0510)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

CDK4/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic Adenocarcinoma

  • Salvador-Barbero, Beatriz
  • Álvarez-Fernández, Mónica
  • Zapatero-Solana, Elisabet
  • Bakkali, Aicha El
  • Camino Menéndez, María del
  • López-Casas, Pedro P.
  • Domenico, Tomas Di
  • Xie, Tao
  • VanArsdale, Todd
  • Shields, David J.
  • Hidalgo, Manuel M.
  • Malumbres, Marcos
Inhibition of the cell-cycle kinases CDK4 and CDK6 is now part of the standard treatment in advanced breast cancer. CDK4/6 inhibitors, however, are not expected to cooperate with DNA-damaging or antimitotic chemotherapies as the former prevent cell-cycle entry, thus interfering with S-phase- or mitosis-targeting agents. Here, we report that sequential administration of CDK4/6 inhibitors after taxanes cooperates to prevent cellular proliferation in pancreatic ductal adenocarcinoma (PDAC) cells, patient-derived xenografts, and genetically engineered mice with Kras G12V and Cdkn2a-null mutations frequently observed in PDAC. This effect correlates with the repressive activity of CDK4/6 inhibitors on homologous recombination proteins required for the recovery from chromosomal damage. CDK4/6 inhibitors also prevent recovery from multiple DNA-damaging agents, suggesting broad applicability for their sequential administration after available chemotherapeutic agents., M.Á.-F. received young investigator grants from MINECO (SAF2014-60442-JIN, cofinanced by FEDER funds) and the Asociación Española contra el Cancer (AECC). The laboratory of M.M. is supported by grants from MICIU [SAF2015-69920-R and RTI2018-095582-B-I00 (AEI-MICIU/FEDER, UE)], and the iLUNG program from the Comunidad de Madrid (B2017/BMD-3884). CNIO is a Severo Ochoa Center of Excellence (MINECO award SEV-2015-0510)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

An E2F7-dependent transcriptional program modulates DNA damage repair and genomic stability

  • Mitxelena, Jone
  • Apraiz, Aintzane
  • Vallejo-Rodríguez, Jon
  • García-Santisteban, Iraia
  • Fullaondo, Asier
  • Álvarez-Fernández, Mónica
  • Malumbres, Marcos
  • Zubiaga, Ana
The cellular response to DNA damage is essential for maintaining the integrity of the genome. Recent evidence has identified E2F7 as a key player in DNA damage-dependent transcriptional regulation of cell-cycle genes. However, the contribution of E2F7 to cellular responses upon genotoxic damage is still poorly defined. Here we show that E2F7 represses the expression of genes involved in the maintenance of genomic stability, both throughout the cell cycle and upon induction of DNA lesions that interfere with replication fork progression. Knockdown of E2F7 leads to a reduction in 53BP1 and FANCD2 foci and to fewer chromosomal aberrations following treatment with agents that cause interstrand crosslink (ICL) lesions but not upon ionizing radiation. Accordingly, E2F7-depleted cells exhibit enhanced cell-cycle re-entry and clonogenic survival after exposure to ICL-inducing agents. We further report that expression and functional activity of E2F7 are p53-independent in this context. Using a cell-based assay, we show that E2F7 restricts homologous recombination through the transcriptional repression of RAD51. Finally, we present evidence that downregulation of E2F7 confers an increased resistance to chemotherapy in recombination-deficient cells. Taken together, our results reveal an E2F7-dependent transcriptional program that contributes to the regulation of DNA repair and genomic integrity., This work was supported by grants from the Spanish Ministry [SAF2012-33551 and SAF2015-67562-R, co-financed by FEDER funds, and SAF2014-57791-REDC], the Basque Government [IT634-13 and KK-2015/89], and the University of the Basque Country UPV/EHU [UFI11/20] to AMZ; and grants from the Spanish Ministry [SAF2015-69920-R], and Worldwide Cancer Research [15-0278] to MM. JM was recipient of a Basque Government fellowship for graduate studies and JVR is recipient of a UPV/EHU fellowship for graduate studies. M.A.F. was supported by a young investigator grant from MINECO [SAF2014-60442-JIN; co-financed by FEDER funds]. Funding for open access charge: Spanish Ministry [SAF2015-67562-R, co-financed by FEDER funds]; Basque Government [IT634-13]., Peer reviewed